Sialyl-Tn in Cancer: (How) Did We Miss the Target?

Bibliographic Details
Main Author: Sylvain , Julien
Publication Date: 2012
Other Authors: Videira, Paula A, Delannoy, Philippe
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: https://doi.org/10.3390/biom2040435
Summary: http://www.mdpi.com/2218-273X/2/4/435
id RCAP_a2ff779c42bd7a03461b38f459cd6786
oai_identifier_str oai:run.unl.pt:10362/23346
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Sialyl-Tn in Cancer: (How) Did We Miss the Target?ST6GalNAc Icancer immunotherapyTheratopeO-glycanSialyl-Tn antigenSialyl-Tn antigenO-glycanST6GalNAc ITheratopecancer immunotherapySDG 3 - Good Health and Well-beinghttp://www.mdpi.com/2218-273X/2/4/435Sialyl-Tn antigen (STn) is a short O-glycan containing a sialic acid residue a2,6-linked to GalNAca-O-Ser/Thr. The biosynthesis of STn is mediated by a specific sialyltransferase termed ST6GalNAc I, which competes with O-glycans elongating glycosyltransferases and prevents cancer cells from exhibiting longer O-glycans. While weakly expressed by fetal and normal adult tissues, STn is expressed by more than 80% of human carcinomas and in all cases, STn detection is associated with adverse outcome and decreased overall survival for the patients. Because of its pan-carcinoma expression associated with an adverse outcome, an anti-cancer vaccine, named Theratope, has been designed towards the STn epitope. In spite of the great enthusiasm around this immunotherapy, Theratope failed on Phase III clinical trial. However, in lieu of missing this target, one should consider to revise the Theratope design and the actual facts. In this review, we highlight the many lessons that can be learned from this failure from the immunological standpoint, as well as from the drug design and formulation and patient selection. Moreover, an irrefutable knowledge is arising from novel immunotherapies targeting other carbohydrate antigens and STn carrier proteins, such as MUC1, that will warrantee the future development of more successful anti-STn immunotherapy strategies.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Centro de Estudos de Doenças Crónicas (CEDOC)RUNSylvain , JulienVideira, Paula ADelannoy, Philippe2017-09-18T22:00:28Z2012-10-112012-10-11T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article32application/pdfhttps://doi.org/10.3390/biom2040435eng2218-273XPURE: 155930http://www.mdpi.com/2218-273X/2/4/435https://doi.org/10.3390/biom2040435info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-05-22T17:27:43Zoai:run.unl.pt:10362/23346Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T16:59:01.578353Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Sialyl-Tn in Cancer: (How) Did We Miss the Target?
title Sialyl-Tn in Cancer: (How) Did We Miss the Target?
spellingShingle Sialyl-Tn in Cancer: (How) Did We Miss the Target?
Sylvain , Julien
ST6GalNAc I
cancer immunotherapy
Theratope
O-glycan
Sialyl-Tn antigen
Sialyl-Tn antigen
O-glycan
ST6GalNAc I
Theratope
cancer immunotherapy
SDG 3 - Good Health and Well-being
title_short Sialyl-Tn in Cancer: (How) Did We Miss the Target?
title_full Sialyl-Tn in Cancer: (How) Did We Miss the Target?
title_fullStr Sialyl-Tn in Cancer: (How) Did We Miss the Target?
title_full_unstemmed Sialyl-Tn in Cancer: (How) Did We Miss the Target?
title_sort Sialyl-Tn in Cancer: (How) Did We Miss the Target?
author Sylvain , Julien
author_facet Sylvain , Julien
Videira, Paula A
Delannoy, Philippe
author_role author
author2 Videira, Paula A
Delannoy, Philippe
author2_role author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
Centro de Estudos de Doenças Crónicas (CEDOC)
RUN
dc.contributor.author.fl_str_mv Sylvain , Julien
Videira, Paula A
Delannoy, Philippe
dc.subject.por.fl_str_mv ST6GalNAc I
cancer immunotherapy
Theratope
O-glycan
Sialyl-Tn antigen
Sialyl-Tn antigen
O-glycan
ST6GalNAc I
Theratope
cancer immunotherapy
SDG 3 - Good Health and Well-being
topic ST6GalNAc I
cancer immunotherapy
Theratope
O-glycan
Sialyl-Tn antigen
Sialyl-Tn antigen
O-glycan
ST6GalNAc I
Theratope
cancer immunotherapy
SDG 3 - Good Health and Well-being
description http://www.mdpi.com/2218-273X/2/4/435
publishDate 2012
dc.date.none.fl_str_mv 2012-10-11
2012-10-11T00:00:00Z
2017-09-18T22:00:28Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.3390/biom2040435
url https://doi.org/10.3390/biom2040435
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2218-273X
PURE: 155930
http://www.mdpi.com/2218-273X/2/4/435
https://doi.org/10.3390/biom2040435
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 32
application/pdf
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833596339959627776

Similar Items